Prevalence of asthma in patients with atopic dermatitis: A systematic review and meta-analysis - 11/01/21
Abstract |
Background |
It is well established that asthma is common in patients with atopic dermatitis (AD).
Objectives |
We performed a systematic review and meta-analysis to determine the prevalence of asthma and respiratory symptoms in individuals with AD as well as the association between AD and asthma.
Methods |
At least 2 authors independently searched the medical databases PubMed, EMBASE, LILACS, and SCOPUS for all English-language studies with data on asthma prevalence among patients with AD or the association between AD and asthma. Pooled odds ratios with 95% confidence intervals (CIs) and pooled proportions were estimated with random-effects models. The Newcastle-Ottawa scale was used to assess study quality.
Results |
The search yielded 39,503 articles. Of these, 213 studies were included in a quantitative analysis. The overall pooled prevalence of asthma was 25.7% (95% CI, 23.7-27.7) in patients with AD and 8.1% (95% CI, 7.0-9.4) among reference individuals. There was a significant association between AD and asthma when compared with reference individuals (odds ratio, 3.03; 95% CI, 2.64-3.47).
Limitations |
The definitions of AD and asthma differed across the included studies and varied from self-report to physician diagnosed.
Conclusions |
Asthma is a common comorbidity of AD. Physicians should be cognizant of this relationship and address asthma symptoms in their patients.
Le texte complet de cet article est disponible en PDF.Key words : association, atopic dermatitis, asthma, eczema, meta-analysis, prevalence, systematic review
Abbreviations used : AD, CI, Ig, IL, NOS, OR, Th
Plan
| Funding sources: None. |
|
| Disclosure: Dr Silverberg has received honoraria as an advisory board member or consultant from AbbVie, Anaptysbio, Asana, Eli Lilly, Galderma, GlaxoSmithKline, Kiniksa, LEO Pharma, Menlo, Pfizer, Regeneron-Sanofi, Realm, and Roivant and as a speaker for Regeneron-Sanofi. Dr Egeberg has received research funding from Pfizer, Eli Lilly, the Danish National Psoriasis Foundation, and the Kgl Hofbundtmager Aage Bang Foundation and honoraria as a consultant and/or speaker from AbbVie, Almirall, Bristol-Meyers Squibb, Dermavant, LEO Pharma, Samsung Bioepis, UCB, Pfizer, Eli Lilly, Novartis, Galderma, and Janssen Pharmaceuticals. Dr Thyssen has attended advisory boards for Sanofi-Genzyme, AbbVie, Union Therapeutics, Pfizer, and Eli Lilly; received speaker honoraria from LEO Pharma and Sanofi-Genzyme; and been an investigator for Sanofi-Genzyme, Eli Lilly, LEO Pharma, and AbbVie. Ms Ravnborg and Drs Ambikaibalan, Agnihotri, Price, Rastogi, Patel, Singam, Andersen, and Halling have no conflicts of interest to declare. |
|
| IRB approval status: Not applicable. |
Vol 84 - N° 2
P. 471-478 - février 2021 Retour au numéro
Article précédent
- Joint AAD–NPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures
- Craig A. Elmets, Neil J. Korman, Elizabeth Farley Prater, Emily B. Wong, Reena N. Rupani, Dario Kivelevitch, April W. Armstrong, Cody Connor, Kelly M. Cordoro, Dawn M.R. Davis, Boni E. Elewski, Joel M. Gelfand, Kenneth B. Gordon, Alice B. Gottlieb, Daniel H. Kaplan, Arthur Kavanaugh, Matthew Kiselica, Daniela Kroshinsky, Mark Lebwohl, Craig L. Leonardi, Jason Lichten, Henry W. Lim, Nehal N. Mehta, Amy S. Paller, Sylvia L. Parra, Arun L. Pathy, Michael Siegel, Benjamin Stoff, Bruce Strober, Jashin J. Wu, Vidhya Hariharan, Alan Menter
- Role of phototherapy in the era of biologics
- Angeli Eloise Torres, Alexis B. Lyons, Iltefat H. Hamzavi, Henry W. Lim
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?